Cerezyme: profile and news

Expensive treatment means life for Palestinian children Feb 22, 2006
We were delivering vials of Cerezyme, the only effective medication for treating Gaucher's (pronounced "go-shays"), a rare disease affecting their two young ... - ReliefWeb (press release),

Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006
Genzyme also recorded $16.9 million in charges for unsuccessful production runs of Cerezyme® that occurred as the company’s Allston Landing manufacturing ... - WebWire (press release),

Genzyme Reports Financial Results for Fourth Quarter of 2005 and ... Feb 15, 2006
Genzyme also recorded $16.9 million in charges for unsuccessful production runs of Cerezyme(R) that occurred as the company's Allston Landing manufacturing ... - MSN Money

Genzyme Sticks With Forecast Feb 15, 2006
Newer products will have an increasingly greater impact on the top line as they continue to grow, while Cerezyme sales in 2006 will represent 30% of its ... - TheStreet.com

Genzyme posts 4th-qtr profit as drug sales rise Feb 15, 2006
The company said sales of Cerezyme, its drug to treat Gaucher disease, a condition that causes enlargement of the liver and spleen, will likely reach $970 ... - Reuters

Genzyme posts $2.7B in '05 sales Feb 15, 2006
For example, the company's first major project, the enzyme replacement therapy Cerezyme, five years ago accounted for most of Genzyme's revenue. ... - Boston Business Journal,

Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue Jan 9, 2006
Fourth-quarter sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $232 million, 6 percent greater ... - MSN Money

Genzyme's Revenue Set to Climb Jan 9, 2006
Analysts surveyed by Thomson First Call were expecting revenue of $729.9 million. Sales of one of its top drugs, Cerezyme, climbed 6% to $232 million. ... - TheStreet.com

Genzyme 4th-qtr revenue rises 22 pct on drug sales Jan 9, 2006
Sales of Cerezyme, the company's treatment for Gaucher disease, a condition that causes enlargement of the liver and spleen, rose 6 percent to $232 million. ... - Reuters

S&P Cuts Alberto-Culver Shares to Hold from Buy Jan 10, 2006
Renagel sales of $111 million are in line, $232 million Cerezyme sales were $9 million below our forecast, and $81 million Fabrazyme sales were $1 million below ... - BusinessWeek

Early numbers from Genzyme show 24% revenue rise Jan 9, 2006
Its drug Cerezyme, designed to treat the enzyme disorder Gaucher disease, jumped to $933 million in sales in fiscal 2005, up from $839 million the year before. ... - Boston Business Journal,

BioMarin Establishes Commercial Operations in Europe Jan 10, 2006
...responsible for overseeing the development and implementation of reimbursement planning and launch for multiple products, including Cerezyme and Ceredase. ... - PR Newswire (press release),

Many With Gaucher Unaware of Disease Dec 1, 2005
LaBelle receives intravenous infusions of the latest formulation of the enzyme, called Cerezyme, at a local Minneapolis hospital every other week. ... - The Jewish Journal of greater L.A,

Wall Street Journal Examines High Price of Gaucher Disease ... Nov 16, 2005
The Wall Street Journal on Wednesday examined the high price of Cerezyme -- a treatment for Gaucher disease manufactured by Genzyme -- and profiled a patient ... - Kaiser network.org,

Pharma Reformulates Dec 5, 2005
This class contains such products as Genzyme's Cerezyme, Fabrazyme, and Aldurazyme, the latter codeveloped with BioMarin, plus Shire's agalsidase beta product ... - Chemical & Engineering News

Lack of One Enzyme Triggers Illness Dec 1, 2005
The effects of the symptoms vary, depending on the severity of the disease, but they can be managed with biweekly infusions of Cerezyme, an enzyme manufactured ... - The Jewish Journal of greater L.A,

TransMolecular Expands Management Team Nov 30, 2005
Upon joining Genzyme, Ms. Bock oversaw the clinical drug development of the company's first major product, Cerezyme(R), approved for the treatment of Gaucher ... - Genetic Engineering News,

A biotech drug extends a life, but at what price? Nov 16, 2005
Genzyme enjoys a gross profit margin of more than 90 percent on the drug called Cerezyme, similar to many other successful medicines in the industry. ... - Pittsburgh Post Gazette,

Analysts: Genzyme drug has blockbuster shot Oct 10, 2005
Sales of the company's first major drug, Cerezyme, produced $839 million in revenue from approximately 4,500 patients in 2004 after about a decade on the market ... - MSNBC

CAT imposes competition remedy on Genzyme Oct 4, 2005
...following the CAT's earlier decision on the merits of the case (which found that Genzyme had infringed UK competition law in pricing its Cerezyme drug and ... - Mondaq News Alerts,

Disruptions to continue on Amtrak Boston-NY runs Oct 5, 2005
...has ended with a British agency's ruling that the company must offer home-care providers a 7.2 percent discount on its flagship drug, Cerezyme, the company said ... - Boston Globe,

UK agency says Genzyme must discount drug Oct 4, 2005
...(GENZ.O: Quote, Profile, Research) on Tuesday said a British government agency has ruled the company must discount the price of its Cerezyme drug to homecare ... - Reuters

Q&A: Genzyme’s Alan Smith Oct 5, 2005
...portfolio. We also take some of this discovery money to work on technology platforms. Cerezyme was state-of-the-art 1980s technology. We ... - Red Herring,

"Easy to miss," Gaucher Disease is widespread and treatable Sep 20, 2005
She receives intravenous infusions of the latest formulation of the enzyme, called Cerezyme, at a local Minneapolis hospital every other week. ... - Jewish United Fund,

Genzyme Expands its Research and Manufacturing Presence in ... Oct 5, 2005
Two of Genzyme's major products are currently produced at Allston: Cerezyme® (imiglucerase for injection), an enzyme replacement therapy for Type 1 Gaucher ... - Yahoo! News (press release)

Good news all the way at Genzyme Sep 29, 2005
...first two commercial products will be ‘Thymoglobulin’ which is used to treat acute retention in renal transplant patients, and ‘Cerezyme’, an enzyme ... - Waterford News,

No cure, but Gaucher'sa treatable diseaseSeptember Nat'l Awareness ... Sep 28, 2005
...motherhood. She began Cerezyme therapy, the latest formulation of the missing enzyme delivered through intravenous infusion once a month. ... - Washington Jewish Week,

Physician promotes universal screening for Gaucher's Disease Aug 25, 2005
Gaucher's disease is treated every two weeks with intravenous Cerezyme, which replaces the enzyme not manufactured in sufficient quantities by patients with ... - Jewish Review,

This girl is alive thanks to US generosity Aug 21, 2005
Manufactured synthetically by a US company, Genzyme, Prachi needs the injections, called Cerezyme, to survive. How important are these injections? ... - Mid-Day Mumbai,

Genzyme seeks OK for Pompe disease drug Jul 30, 2005
...storage disorders. It would join Cerezyme, which has 4,400 patients, and a newer drug called Fabrazyme, with about 1,500. Genzyme ... - Boston Globe

Leading Biotech Company To Host Fieldbus Seminar Aug 3, 2005
Genzyme. Commercial products currently produced at Allston Landing include: Cerezyme, Fabrazyme, Thyrogen and Aldurazyme. Catherine ... - Automation.com (press release)

From orphan to blockbuster? Jul 8, 2005
The company's top-selling drug, Cerezyme, treats 4,500 patients with Gaucher and generated $839 million in 2004 sales. The Boston ... - CNN

Genzyme profits leap 58 in 2d quarter Jul 14, 2005
Though much of Genzyme's sales still come from Cerezyme, a treatment for a rare genetic disorder called Gaucher disease, the company yesterday reported ... - Boston Globe

UPDATE 3-Genzyme 2nd-quarter profit jumps 58 percent Jul 14, 2005
..."It's amazing what's happened to this company considering they used to be one product line.". That product, Cerezyme, saw sales grow 13 percent to $236 million. ... - Reuters

Business briefs Jul 15, 2005
CAMBRIDGE -- Genzyme Corp., the fourth-largest US biotechnology company, said quarterly profit jumped 58 percent on higher sales of its Cerezyme and Fabrazyme ... - Worcester Telegram (subscription)

Genzyme's Myozyme Now On File, Seeking Priority Review Jul 29, 2005
Already that formula has worked for Cerezyme (imiglucerase), the Gaucher's disease treatment that is approved in almost 80 countries, and Fabrazyme (agalsidase ... - BioWorld Online (subscription)

Genzyme 2nd-quarter profit jumps 58 percent Jul 14, 2005
Revenue rose to $668.1 million from $549.6 million a year earlier, led by sales of Cerezyme, a treatment for Gaucher disease, kidney disease drug Renagel, and ... - Reuters

Genzyme reports robust earnings Jul 14, 2005
The company saw strong growth amongst several of its product lines, including Renagel, Cerezyme, Fabrazyme, Thyrogen and Synvisc. ... - MarketWatch

Genzyme "outperform," target price raised Jul 15, 2005
The upside was driven by robust revenues and margins from the Cerezyme, Synvisc and Thyrogen drugs, which more than offset the sluggish sales of the Renagel ... - New Ratings

Genzyme posts profit jump, ups outlook Jul 14, 2005
Cerezyme, another enzyme replacement therapy and one of Genzyme's largest revenue sources, saw its sales increase 13 percent to $236 million. ... - BusinessWeek

Transkaryotic Therapies: What's It Worth? Jul 25, 2005
...from Dynepo against entrenched and generic competition and the failure of GA-GCB to gain significant traction against Genzyme's (Nasdaq: GENZ) Cerezyme. ... - Motley Fool

Genzyme Reports Second-Quarter GAAP EPS of $0.46, Non-GAAP EPS of ... Jul 14, 2005
Sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $236.0 million in the second quarter, 13 percent ... - Yahoo News (press release)

Zacks.com Announces That Joseph Parnes Highlights the Following ... Jul 22, 2005
...$549.6 million. The Genzyme's largest source "Cerezyme" and enzyme replacement therapy saw its sale up to $236 million +13%. Stanley ... - Business Wire (press release)

Genentech, Genzyme poised for higher earnings Jul 7, 2005
..."Fabrazyme could be a blockbuster," said Reames, adding it could eventually have higher sales than the company's lead drug Cerezyme, which is used to treat ... - MarketWatch

US Stocks Gain, Boosted by Apple Shares and Retail Report Jul 14, 2005
4 US biotechnology company, advanced $4.06 to $65.40 after saying second-quarter profit jumped 58 percent on higher sales of its Cerezyme and Fabrazyme genetic ... - Bloomberg

AROUND THE NATION Jul 14, 2005
Genzyme Corp., the fourth-biggest US biotechnology company, said quarterly profit jumped 58 percent on higher sales of its Cerezyme and Fabrazyme genetic ... - Houston Chronicle

S&P Keeps Hold on Apple Jul 14, 2005
Renagel sales of $100.8 million were $3 million below our forecast, Cerezyme's $236 million were $6 million above, and Fabrazyme's $74.4 million were in line. ... - BusinessWeek

Rare Diseases Mean Solid Growth for Genzyme Jul 18, 2005
Sales of Cerezyme climbed 13% to $236 million, Renagel sales climbed 15% to slightly less than $101 million, and sales of the relatively new Fabrazyme jumped 50 ... - MSNBC

Genzyme Beats Estimates; Revenues Jump 22 Percent Jul 14, 2005
In therapeutics, Fabrazyme, an enzyme-replacement therapy for Fabry's disease, increased by 50 percent to $74.4 million, while Cerezyme, an enzyme-replacement ... - BioWorld Online (subscription)

Genzyme and Project HOPE Partner to Rebuild Critical Health Care ... Jul 13, 2005
In developing countries, Genzyme sponsors the Gaucher Initiative through Project HOPE, providing its enzyme replacement therapy Cerezyme® to Gaucher patients ... - Yahoo News (press release)